| Private Placement / Financing Transactions
Actym Therapeutics: The company raised $59.5 million of Series A venture funding in a deal led by Illumina Ventures and Boehringer Ingelheim Venture Fund on October 18, 2023, putting the company’s pre-money valuation at $15 million. Panacea Venture, Korea Investment Partners, JLo Ventures, and GKCC LLC also participated in the round. The company is a developer of a therapeutic platform that uses a genetically modified bacterial vehicle to achieve therapeutic impact for cancer patients across multiple tumor types.
Nucleus RadioPharma: The company raised $56 million of Series A venture funding from Mayo Clinic, GE Healthcare and Eclipse Ventures on October 17, 2023, putting the company’s pre-money valuation at $150 million. University of Missouri and other undisclosed investors also participated in the round. The company is a developer of novel treatments and technology in cancer research designed to provide patients access to therapeutic radiopharmaceuticals.
Debut: The company raised $40 million of Series B venture funding in a deal led by BOLD (Business Opportunities for L’Oréal Development) on October 19, 2023. Cavallo Ventures, DIC Group, GS Futures, Touchdown Ventures, Material Impact Fund, Sandbox Industries, Fine Structure Ventures and ACVC Partners also participated in the round. The company is a developer of a cell-free biomanufacturing technology focused on ingredient discovery and formulation for skincare and fragrance products.
Amplifier Therapeutics: The company raised $33.3 million of Series A venture funding in a deal led by Cambrian Bio on October 17, 2023. Future Ventures, RA Capital Management and other undisclosed investors also participated in the round. The company uses biopharmaceutical technology to discover the therapeutic applications of AMP-activated protein kinase (AMPK) for age related illness such as metabolic conditions, cardio vascular disease and cancer.
VedaBio: The company raised an estimated $40 million through a combination of Series A-4 and Series A venture funding in a deal led by OMX Ventures on October 17, 2023, putting the company’s pre-money valuation at $50 million. Kleinmuntz Associates and other undisclosed investors also participated in the round. The company is a developer of molecular diagnostics equipment designed to bring PCR accuracy in antigen testing.
DermBiont: The company raised $26.6 million of venture funding from undisclosed investors on October 19, 2023. The company is a developer of microbial therapeutics designed to impact the root causes of skin diseases.
Rejoni: The company raised $26.3 million of Series B venture funding in a deal led by Catalyst Health Ventures on October 18, 2023. Ascension Ventures, AMED Ventures, Iyengar Capital Partners, Delos Capital Partners, FemHealth Ventures and Sparta Group also participated in the round. The company is a developer of surgical instruments that minimize acute and chronic risks associated with gynecologic procedures.
4D Lifetec: The company is in the process of raising CHF 23.3 million of venture funding from Xlife Sciences on October 18, 2023. It plans to close the round by November 2023. The company is a developer of a clinical platform that offers a molecular diagnostic test system for early detection and public screening of cancer.
Endogenex: The company raised an additional $18.3 million of Series B-1 venture funding from undisclosed investors on October 17, 2023, putting the company’s pre-money valuation at $61.2 million. The company is a developer of a novel endoscopic procedure designed to treat diabetes.
Biocogniv: The company raised $10.7 million of venture funding from undisclosed investors on October 19, 2023. The company combines laboratory medicine, AI technology, and evidence-based acute care, to reduce preventable hospital deaths, morbidities, and cost of care.
Darmiyan: The company raised $3.5 million of Series A venture funding from SOMPO and other undisclosed investors on October 17, 2023, putting the company’s pre-money valuation at $48.5 million. The company is a developer of a brain imaging technology designed to offer early detection, visualization, and quantification of neurodegenerative disorders.
i2O Therapeutics: The company raised $3.5 million of venture funding from HM Venture Partners, and undisclosed investors on October 18, 2023. The company is a developer of ionic liquid technology designed to treat metabolic and inflammatory diseases.
Entopsis: The company is in the process of raising venture funding on October 19, 2023. The company is a developer of novel diagnostic technologies designed to improve early detection and treatment of cancer, autoimmune disorders and rare diseases .
Variantyx: The company raised an undisclosed amount of venture funding from Bosch Ventures, Peregrine Ventures and Pitango Venture Capital on October 18, 2023. New Era Capital Partners and 20/20 HealthCare Partners also participated in the round. The company is a developer of a whole genome analytical technology designed to diagnose and generate clinical reports for rare inherited disorders.
|
